BOSTON (AP) - The withdrawal of a new multiple sclerosis drug has focused scrutiny on millions of dollars in insider stock sales at Biogen Idec Inc. and executive bonuses awarded before the company disclosed a death and illness that led to the drug's removal from the market....More
Thursday, March 03, 2005
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment